Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2014 | Trial shows CAR T-cell therapy prolongs remission in paediatric relapsed or refractory ALL

Stephan Grupp • 5 Dec 2014
ASH 2014
Acute Lymphoblastic Leukemia

At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Stephan Grupp (Children’s Hospital of Philadelphia and University of Pennsylvania, Philadelphia, PA) presents the results of a study that suggests chimeric antigen receptor (CAR) T cells targeting CD19 (CTL019) can elicit durable remissions in paediatric relapsed or refractory acute lymphocytic leukaemia (ALL).

More from Stephan Grupp

1:33
Patient selection for CAR-T in ALL
Stephan Grupp • 2 Sep 2021
2:16
The latest research in ALL cellular therapy
Stephan Grupp • 2 Sep 2021
1:21
The future of treating pediatric ALL with CAR-T
Stephan Grupp • 2 Sep 2021
0:57
The importance of common language for CAR-T
Stephan Grupp • 18 Mar 2021

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
1:15
Comparing the efficacy of salvage therapies in adult B-ALL: a retrospective real-world study
Alex Rampotas • 16 Apr 2024
3:34
Total marrow and lymphoid irradiation plus cyclophosphamide & etoposide in poor-risk acute leukemias
Anthony Stein • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals